GLP-1 Treatment Guide: Starting, Titrating, Maintaining (2026)
A GLP-1 treatment walkthrough — from initial evaluation through titration, maintenance, and what happens after discontinuation, stage by stage.
GLP-1 treatment is conceptually simple — you take a weekly injection or daily pill, your appetite drops, you lose weight, your metabolic markers improve. The reality is more involved: there's an evaluation phase, a titration phase that runs 4-5 months, a maintenance phase that ideally runs indefinitely, and the question of what happens if you stop.
This is the full treatment journey, from the first conversation to the long-term maintenance plan.
Phase 1: Eligibility evaluation
The first step is determining whether GLP-1 treatment is appropriate for you.
FDA-label eligibility criteria
For the weight-management GLP-1s (Wegovy, Zepbound, Saxenda, Wegovy oral, Foundayo):
- BMI ≥ 30 (obesity), OR
- BMI ≥ 27 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, etc.)
For T2D-indicated drugs (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza, Byetta, Adlyxin):
- Diagnosis of type 2 diabetes
Contraindications
GLP-1s are not appropriate for:
- Personal or family history of medullary thyroid carcinoma or MEN-2
- Personal history of pancreatitis
- Severe gastroparesis
- Pregnancy or near-term pregnancy plans
- Active or recent eating disorder
- Type 1 diabetes
Baseline workup
A reasonable initial evaluation includes:
- Comprehensive medical history (especially the contraindications above)
- Weight, height, BMI, waist circumference, blood pressure
- HbA1c (diabetes screening / baseline)
- Comprehensive metabolic panel
- Lipid panel
- Thyroid function (TSH at minimum)
- Pregnancy test for patients of childbearing capacity
- Vitamin B12 and vitamin D (often deficient in weight-loss patients)
Phase 2: Drug selection
Decision factors, in order of typical impact:
- Insurance coverage — what's covered, at what tier?
- Indication — T2D vs weight management vs both?
- Dosing preference — weekly injection / daily injection / daily oral?
- Tolerability factors — comorbidities affecting drug choice
- Cost beyond insurance — savings programs, telehealth bundles, etc.
For the head-to-head comparison, see best GLP-1 for weight loss.
Phase 3: Titration
Every approved GLP-1 follows a slow titration schedule designed to manage gastrointestinal side effects.
Typical pattern (Wegovy as example):
| Week | Dose |
|---|---|
| 1-4 | 0.25 mg/week |
| 5-8 | 0.5 mg/week |
| 9-12 | 1.0 mg/week |
| 13-16 | 1.7 mg/week |
| 17+ | 2.4 mg/week (target) |
Tirzepatide (Zepbound/Mounjaro) follows a similar 4-weekly escalation pattern. Daily drugs (Saxenda, Foundayo) titrate weekly rather than every 4 weeks.
What to expect during titration:
- Most side effects (nausea, GI symptoms) hit hardest in the days after a dose increase, then settle within 1-2 weeks
- Weight loss is gradual through this phase — averages 1% body weight per month
- Significant weight loss usually doesn't emerge until weeks 8-12
- Most patients reach target dose by week 16-17
When to slow titration:
If side effects haven't settled within a week or two of a dose increase, the prescriber may hold the dose for an extra cycle before stepping up.
For the full dose schedules, see GLP-1 dosage for weight loss.
Phase 4: Maintenance
Once at target dose, the maintenance phase runs indefinitely for most patients.
What's involved:
- Weekly (or daily) injection / oral dose
- Monthly check-ins with the prescriber (more often early; less frequent as you stabilize)
- Regular labs: HbA1c, lipids, comprehensive metabolic panel, vitamin levels every 3-6 months
- Dose adjustments as response and tolerability change
Realistic timeline of effects:
- Months 1-6: Steady weight loss, ~1-2% body weight per month
- Months 6-12: Continued loss, trajectory slowing
- Months 12-18: Approach of plateau; trial-average weight loss reached
- Months 18+: Maintenance at the new weight; weight remains stable as long as the medication continues
Phase 5: The plateau
Weight loss plateaus by 12-18 months for most patients. This isn't failure — it's the body reaching a new homeostasis at a lower weight.
What to expect at plateau:
- Weight loss largely stops
- Appetite remains suppressed but is no longer driving deficit
- Body composition stabilizes
- Metabolic markers stabilize at improved levels
Decisions at plateau:
- Continue at maintenance dose — most common; lifelong treatment
- Reduce to lower maintenance dose — sometimes appropriate; preserves loss with lower cost and side effects
- Switch to oral maintenance — emerging option per Lilly's Foundayo Phase 3 data showing 80-95% maintenance after switching from injectable
- Discontinuation conversation — for selected patients with strong lifestyle infrastructure (resistance training, protein intake, sleep, etc.)
Phase 6: Discontinuation (when, why, what to expect)
GLP-1 discontinuation is not the standard endpoint of treatment, but it happens. Common reasons:
- Side effects persistently intolerable
- Side effects of long-term use (rare)
- Pregnancy plans
- Cost when insurance changes
- Patient choice — wanting to test maintenance off medication
- Required medical hold — surgery, illness, gastroparesis flare
What happens after discontinuation:
- Drug clearance: Semaglutide and tirzepatide take weeks to clear; liraglutide clears in 2-3 days; small-molecule oral drugs clear in days
- Appetite returns: Within 2-4 weeks for most patients
- Weight regain: Studies show patients regain 50-70% of lost weight within 12 months if they don't continue the medication or maintain with significant lifestyle change
The honest framing: GLP-1 treatment for chronic conditions (obesity, T2D) is conceptually similar to treating hypertension or high cholesterol. The condition doesn't "cure"; the treatment is ongoing.
What "good" GLP-1 treatment looks like
A few markers of well-managed treatment:
- Slow, supervised titration — not skipping steps
- Side-effect management — practical strategies, not just gritting through
- Lifestyle integration — resistance training, protein, sleep, fiber
- Regular labs and follow-up — at least every 3-6 months
- Long-term mindset — not framing this as a short course
- Honest conversations about cost, alternatives, and timeline
Red flags in GLP-1 treatment
Indicators that something needs adjustment:
- Sustained severe nausea beyond 2-3 weeks of a dose step
- Inability to keep fluids down for more than 24 hours
- Severe abdominal pain — possible pancreatitis or gallbladder
- Eating < 1,000 calories/day consistently — undereating
- Strength regression in resistance training — possible muscle loss
- Persistent low mood or anxiety
- No weight loss after 8-12 weeks at target dose — non-responder pattern, may need to switch drugs
FAQ
How long does GLP-1 treatment last? For chronic conditions (obesity, T2D), treatment is typically indefinite. Patient-specific decisions about duration are common.
Will I have to take a GLP-1 forever? Most patients do continue treatment indefinitely. Some maintain weight loss with significant lifestyle change after discontinuation; many don't.
What if a GLP-1 doesn't work for me? About 10-15% of patients are non-responders. Switching to a different GLP-1 (typically a more potent dual-receptor option) sometimes works. Pipeline drugs may help when approved.
Can I switch GLP-1s mid-treatment? Yes. Switches are common for insurance, supply, or tolerability reasons. Conversion is non-trivial and managed by the prescriber.
What's the lowest dose I should stay on long-term? The lowest effective dose that maintains your weight and tolerates well. Discuss with your prescriber.
This article is for educational purposes only and is not medical advice. GLP-1 treatment is highly individual. Discuss your treatment plan with a qualified healthcare professional.